Tempest Therapeutics (TPST) Free Cash Flow (2012 - 2025)

Tempest Therapeutics has disclosed Free Cash Flow across 14 years of filings, most recently posting -$3.6 million for Q4 2025.

• In Q4 2025, Free Cash Flow rose 64.8% year-over-year to -$3.6 million; the TTM figure through Dec 2025 stood at -$26.8 million (up 19.85% YoY), while the FY2025 annual figure was -$26.8 million, up 19.85% from the prior year.
• Free Cash Flow came in at -$3.6 million for Q4 2025 at Tempest Therapeutics, up from -$6.8 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $57000.0 in Q2 2021 to a low of -$11.8 million in Q3 2021.
• Average Free Cash Flow over 5 years is -$7.3 million, with a median of -$7.2 million recorded in 2022.
• Year-over-year, Free Cash Flow surged 96.55% in 2021 and slumped 15028.07% in 2022.
• Over 5 years, Free Cash Flow stood at -$8.0 million in 2021, then advanced by 14.69% to -$6.8 million in 2022, then gained by 9.55% to -$6.2 million in 2023, then tumbled by 64.22% to -$10.2 million in 2024, then jumped by 64.8% to -$3.6 million in 2025.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$3.6 million in Q4 2025, -$6.8 million in Q3 2025, and -$8.4 million in Q2 2025.